arrow
S

Sonja Zweegman

Cancer Center Amsterdam
H指数:87
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiple myeloma in the Netherlands: 35-year trends in incidence and survival

荷兰多发性骨髓瘤:35年发病率和生存趋势

Leukemia
IF13.4
2026-10-220
OAAI
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

MAIA虚弱亚组分析:在移植不适用的 newly diagnosed myeloma 患者中使用达拉珠单抗联合来那度胺/地塞米松的长-term随访

Leukemia
IF13.4
2026-10-060
OAAI
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

达拉妥单抗联合硼替佐米、来那度胺和地塞米松在延迟移植的新诊断多发性骨髓瘤中的应用:CEPHEUS研究中的虚弱亚组分析

Leukemia
IF13.4
2026-08-180
OA
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study

新诊断多发性骨髓瘤患者SLIM标准下的临床结局:CASSIOPEIA研究中的亚组分析

Leukemia
IF13.4
2026-08-130
PRE
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS

达鲁珠单抗在移植不适用或延迟的 newly diagnosed multiple myeloma 中的研究:CEPHEUS 试验中的微小残留病

2026-06-050
OAAI
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE

达拉妥单抗治疗新诊断多发性骨髓瘤患者的感染:MAIA和ALCYONE研究的合并分析

2026-05-070
OAAI
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial

FDG-PET骨髓总肿瘤体积在CASSIOPEIA试验中凸显高风险新诊断多发性骨髓瘤患者

2026-03-310
OAAI
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome

揭示超脆弱人群:非移植适应症的 newly diagnosed 多发性骨髓瘤患者中的一个独特亚组,具有较差的临床结局

2025-12-080
OAAI
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

BCMA-和GPRC5D靶向免疫疗法在多发性骨髓瘤中的序贯治疗:欧洲骨髓瘤网络实用指南

2025-11-250
OAAI
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

帕博利珠单抗替代给药方案在多发性骨髓瘤治疗中的药代动力学和药效动力学评价

2025-11-030
OAAI
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial

随机临床试验中的适应性设计:HOVON87/NMSG18多发性骨髓瘤试验的再分析

2025-10-300
OAAI
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

基于EMN–HARMONY联盟平台的机器学习风险分层策略用于多发性骨髓瘤:见解

2025-10-090
OAAI
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels

老年新诊断多发性骨髓瘤患者的免疫特征与一线治疗的生存结局相关,且与脆弱性水平无关。

2025-10-050
OAAI
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

CEPHEUS研究的简明语言摘要:达拉木单抗联合硼替佐米、来那度胺和地塞米松,用于预期不接受干细胞移植的新诊断多发性骨髓瘤患者。

2025-10-010
PRE
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

CASSIOPEIA试验中,新诊断多发性骨髓瘤患者维持治疗前的FDG PET/CT反应的预后价值

Blood
IF23.1
2025-09-260
PRE
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network

多发性骨髓瘤患者静脉血栓栓塞症的预防与治疗:欧洲骨髓瘤网络临床实践指南

2025-08-260
OAAI
A T-cell-based metric of immune age predicts outcomes in elderly myeloma patients receiving daratumumab-based therapy

基于T细胞的免疫年龄指标可预测接受达雷木单抗为基础疗法的老年骨髓瘤患者的结局

Blood
IF23.1
2025-08-210
PRE